Sean E. Browne Net Worth

The estimated Net Worth of Sean E Browne is at least $2.2 Million dollars as of 18 October 2022. Mr Browne owns over 131,100 units of Xtant Medical Inc stock worth over $926,549 and over the last 5 years he sold XTNT stock worth over $85,215. In addition, he makes $1,189,808 as Pres und CEO & Director at Xtant Medical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Browne XTNT stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Xtant Medical Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 131,100 units of XTNT stock worth $85,215 on 18 October 2022.

The largest trade he's ever made was selling 131,100 units of Xtant Medical Inc stock on 18 October 2022 worth over $85,215. On average, Mr trades about 16,388 units every 0 days since 2019. As of 18 October 2022 he still owns at least 1,506,584 units of Xtant Medical Inc stock.

You can see the complete history of Mr Browne stock trades at the bottom of the page.

Mr. Sean E. Browne biography

Sean E. Browne is the Pres, CEO & Director at Xtant Medical Inc.

What is the salary of Mr Browne?

As the Pres und CEO & Director of Xtant Medical Inc, the total compensation of Mr Browne at Xtant Medical Inc is $1,189,808. There are no executives at Xtant Medical Inc getting paid more.

How old is Mr Browne?

Mr Browne is 55, he's been the Pres und CEO & Director of Xtant Medical Inc since . There are 4 older and 3 younger executives at Xtant Medical Inc. The oldest executive at Xtant Medical Holdings Inc is Darrel Holmes, 62, who is the Chief Operating Officer.

What's Mr Browne's mailing address?

Sean's mailing address filed with the SEC is Cruiser Lane, Belgrade, Gallatin County, Montana, 59714, United States.

Insiders trading at Xtant Medical Inc

Over the last 9 years, insiders at Xtant Medical Inc have traded over $104,833 worth of Xtant Medical Inc stock and bought 5,164,288 units worth $21,623,047 . The most active insiders traders include Stavros G. Vizirgianakis, Advisors Llc Orbimed und Matthew Rizzo. On average, Xtant Medical Inc executives and independent directors trade stock every 117 days with the average trade being worth of $134,096. The most recent stock trade was executed by Kevin D Brandt on 17 November 2023, trading 41,670 units of XTNT stock currently worth $50,004.

What does Xtant Medical Inc do?

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.

Complete history of Mr Browne stock trades at Xtant Medical Inc

Xtant Medical Inc executives and stock owners

Xtant Medical Inc executives and other stock owners filed with the SEC include:

• Sean E. Browne,
  Pres, CEO & Director
• Kevin D. Brandt,
  Sr. VP & Chief Commercial Officer
• Darrel Holmes,
  Chief Operating Officer
• Gregory Juda,
  Chief Scientific Officer
• Rich Cockrell,
  IR Contact Officer
• Matthew Rizzo,
  Director
• Jeffrey Peters,
  Director
• Robert McNamara,
  Director
• Michael Eggenberg,
  Director
• John Bakewell,
  Director
• Kevin Brandt,
  Senior Vice President, Chief Commercial Officer
• Greg Jensen,
  Chief Financial Officer, Vice President - Finance
• Sean Browne,
  President, Chief Executive Officer, Director
• Kevin M. O'Dare,
  VP of Sales - Eastern US
• Catherine Lundy,
  VP of HR
• Scott Neils,
  Interim CFO & Controller
• Scott C Neils,
  Chief Financial Officer
• Jonn R. Beeson,
  Director
• Eric Bernard Timko,
  Director
• Kent L Swanson,
  Director
• John Arthur Deedrick,
  Director
• David Louis Kirschman,
  EVP & Chief Scientific Officer
• Daniel S Goldberger,
  Chief Executive Officer
• Rudy A Mazzocchi,
  Director
• Jon M. Wickwire,
  
• David Goodman,
  
• Paul Buckman,
  Director
• Michael A Lopach,
  Director
• Advisors Llc Orbimed,
  Director
• Kathie J. Lenzen,
  Chief Financial Officer
• Carl O'connell,
  Chief Executive Officer
• Michael Mainelli,
  Interim CEO
• Ronald G. Berlin,
  VP & Chief Operations Officer
• Advisors Llc Orbimed Rof Ii...,
  
• Lori D Mitchell Keller,
  Director
• Mark A. Schallenberger,
  Chief Operations Officer
• Stavros G. Vizirgianakis,
  Director